【調査レポート】血液悪性腫瘍治療薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Hematological Malignancy Drugs Market Insights, Forecast to 2028

QYResearchが調査・発行した産業分析レポートです。血液悪性腫瘍治療薬のグローバル市場インサイト・予測（～2028年） / Global Hematological Malignancy Drugs Market Insights, Forecast to 2028 / MRC2Q12-16774資料のイメージです。

• レポートコード：MRC2Q12-16774
• 出版社/出版日：QYResearch / 2022年12月
• レポート形態：英文、PDF、115ページ
• 納品方法：Eメール（納期：3営業日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

コロナ禍により、血液悪性腫瘍治療薬の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に血液悪性腫瘍治療薬のグローバル市場のxxx％を占める「モノクローナル抗体」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「ALL」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
血液悪性腫瘍治療薬の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの血液悪性腫瘍治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

血液悪性腫瘍治療薬のグローバル主要プレイヤーには、Roche、Celgene、Novartis、Bristol-Myers Squibb、Johnson & Johnson、Merck & Co.、AstraZeneca、Pfizer、Amgen、Eli Lilly、AbbVie、Takeda、Sanofi、Bayer、Biogen Idecなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

血液悪性腫瘍治療薬市場は、種類と用途によって区分されます。世界の血液悪性腫瘍治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
モノクローナル抗体、免疫調節薬、チロシンキナーゼ阻害剤、プロテアソーム阻害剤、その他

【用途別セグメント】
ALL、CLL、AML、NHL、DLBCL、MM、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 血液悪性腫瘍治療薬製品概要
- 種類別市場（モノクローナル抗体、免疫調節薬、チロシンキナーゼ阻害剤、プロテアソーム阻害剤、その他）
- 用途別市場（ALL、CLL、AML、NHL、DLBCL、MM、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の血液悪性腫瘍治療薬販売量予測2017-2028
- 世界の血液悪性腫瘍治療薬売上予測2017-2028
- 血液悪性腫瘍治療薬の地域別販売量
- 血液悪性腫瘍治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別血液悪性腫瘍治療薬販売量
- 主要メーカー別血液悪性腫瘍治療薬売上
- 主要メーカー別血液悪性腫瘍治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（モノクローナル抗体、免疫調節薬、チロシンキナーゼ阻害剤、プロテアソーム阻害剤、その他）
- 血液悪性腫瘍治療薬の種類別販売量
- 血液悪性腫瘍治療薬の種類別売上
- 血液悪性腫瘍治療薬の種類別価格
・用途別市場規模（ALL、CLL、AML、NHL、DLBCL、MM、その他）
- 血液悪性腫瘍治療薬の用途別販売量
- 血液悪性腫瘍治療薬の用途別売上
- 血液悪性腫瘍治療薬の用途別価格
・北米市場
- 北米の血液悪性腫瘍治療薬市場規模（種類別、用途別）
- 主要国別の血液悪性腫瘍治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの血液悪性腫瘍治療薬市場規模（種類別、用途別）
- 主要国別の血液悪性腫瘍治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の血液悪性腫瘍治療薬市場規模（種類別、用途別）
- 主要国別の血液悪性腫瘍治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の血液悪性腫瘍治療薬市場規模（種類別、用途別）
- 主要国別の血液悪性腫瘍治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの血液悪性腫瘍治療薬市場規模（種類別、用途別）
- 主要国別の血液悪性腫瘍治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Roche、Celgene、Novartis、Bristol-Myers Squibb、Johnson & Johnson、Merck & Co.、AstraZeneca、Pfizer、Amgen、Eli Lilly、AbbVie、Takeda、Sanofi、Bayer、Biogen Idec
・産業チェーン及び販売チャネル分析
- 血液悪性腫瘍治療薬の産業チェーン分析
- 血液悪性腫瘍治療薬の原材料
- 血液悪性腫瘍治療薬の生産プロセス
- 血液悪性腫瘍治療薬の販売及びマーケティング
- 血液悪性腫瘍治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 血液悪性腫瘍治療薬の産業動向
- 血液悪性腫瘍治療薬のマーケットドライバー
- 血液悪性腫瘍治療薬の課題
- 血液悪性腫瘍治療薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Hematological Malignancy Drugs Market
The global Hematological Malignancy Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Monoclonal Antibody accounting for % of the Hematological Malignancy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While ALL segment is altered to an % CAGR throughout this forecast period.
China Hematological Malignancy Drugs market size is valued at US$ million in 2021, while the North America and Europe Hematological Malignancy Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Hematological Malignancy Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hematological Malignancy Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hematological Malignancy Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hematological Malignancy Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hematological Malignancy Drugs market.
Global Hematological Malignancy Drugs Scope and Market Size
Hematological Malignancy Drugs market is segmented by players, region (country), by Type and by Indication. Players, stakeholders, and other participants in the global Hematological Malignancy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Indication for the period 2017-2028.
Segment by Type
Monoclonal Antibody
Immunomodulatory Drug
Tyrosine Kinase Inhibitor
Proteasome Inhibitors
Others
Segment by Indication
ALL
CLL
AML
NHL
DLBCL
MM
Others
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Sanofi
Bayer
Biogen Idec
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematological Malignancy Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Monoclonal Antibody
1.2.3 Immunomodulatory Drug
1.2.4 Tyrosine Kinase Inhibitor
1.2.5 Proteasome Inhibitors
1.2.6 Others
1.3 Market by Indication
1.3.1 Global Hematological Malignancy Drugs Market Size Growth Rate by Indication, 2017 VS 2021 VS 2028
1.3.2 ALL
1.3.3 CLL
1.3.4 AML
1.3.5 NHL
1.3.6 DLBCL
1.3.7 MM
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hematological Malignancy Drugs Market Perspective (2017-2028)
2.2 Hematological Malignancy Drugs Growth Trends by Region
2.2.1 Hematological Malignancy Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Hematological Malignancy Drugs Historic Market Size by Region (2017-2022)
2.2.3 Hematological Malignancy Drugs Forecasted Market Size by Region (2023-2028)
2.3 Hematological Malignancy Drugs Market Dynamics
2.3.1 Hematological Malignancy Drugs Industry Trends
2.3.2 Hematological Malignancy Drugs Market Drivers
2.3.3 Hematological Malignancy Drugs Market Challenges
2.3.4 Hematological Malignancy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematological Malignancy Drugs Players by Revenue
3.1.1 Global Top Hematological Malignancy Drugs Players by Revenue (2017-2022)
3.1.2 Global Hematological Malignancy Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Hematological Malignancy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hematological Malignancy Drugs Revenue
3.4 Global Hematological Malignancy Drugs Market Concentration Ratio
3.4.1 Global Hematological Malignancy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematological Malignancy Drugs Revenue in 2021
3.5 Hematological Malignancy Drugs Key Players Head office and Area Served
3.6 Key Players Hematological Malignancy Drugs Product Solution and Service
3.7 Date of Enter into Hematological Malignancy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematological Malignancy Drugs Breakdown Data by Type
4.1 Global Hematological Malignancy Drugs Historic Market Size by Type (2017-2022)
4.2 Global Hematological Malignancy Drugs Forecasted Market Size by Type (2023-2028)
5 Hematological Malignancy Drugs Breakdown Data by Indication
5.1 Global Hematological Malignancy Drugs Historic Market Size by Indication (2017-2022)
5.2 Global Hematological Malignancy Drugs Forecasted Market Size by Indication (2023-2028)
6 North America
6.1 North America Hematological Malignancy Drugs Market Size (2017-2028)
6.2 North America Hematological Malignancy Drugs Market Size by Type
6.2.1 North America Hematological Malignancy Drugs Market Size by Type (2017-2022)
6.2.2 North America Hematological Malignancy Drugs Market Size by Type (2023-2028)
6.2.3 North America Hematological Malignancy Drugs Market Share by Type (2017-2028)
6.3 North America Hematological Malignancy Drugs Market Size by Indication
6.3.1 North America Hematological Malignancy Drugs Market Size by Indication (2017-2022)
6.3.2 North America Hematological Malignancy Drugs Market Size by Indication (2023-2028)
6.3.3 North America Hematological Malignancy Drugs Market Share by Indication (2017-2028)
6.4 North America Hematological Malignancy Drugs Market Size by Country
6.4.1 North America Hematological Malignancy Drugs Market Size by Country (2017-2022)
6.4.2 North America Hematological Malignancy Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Hematological Malignancy Drugs Market Size (2017-2028)
7.2 Europe Hematological Malignancy Drugs Market Size by Type
7.2.1 Europe Hematological Malignancy Drugs Market Size by Type (2017-2022)
7.2.2 Europe Hematological Malignancy Drugs Market Size by Type (2023-2028)
7.2.3 Europe Hematological Malignancy Drugs Market Share by Type (2017-2028)
7.3 Europe Hematological Malignancy Drugs Market Size by Indication
7.3.1 Europe Hematological Malignancy Drugs Market Size by Indication (2017-2022)
7.3.2 Europe Hematological Malignancy Drugs Market Size by Indication (2023-2028)
7.3.3 Europe Hematological Malignancy Drugs Market Share by Indication (2017-2028)
7.4 Europe Hematological Malignancy Drugs Market Size by Country
7.4.1 Europe Hematological Malignancy Drugs Market Size by Country (2017-2022)
7.4.2 Europe Hematological Malignancy Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hematological Malignancy Drugs Market Size (2017-2028)
8.2 Asia-Pacific Hematological Malignancy Drugs Market Size by Type
8.2.1 Asia-Pacific Hematological Malignancy Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Hematological Malignancy Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Hematological Malignancy Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Hematological Malignancy Drugs Market Size by Indication
8.3.1 Asia-Pacific Hematological Malignancy Drugs Market Size by Indication (2017-2022)
8.3.2 Asia-Pacific Hematological Malignancy Drugs Market Size by Indication (2023-2028)
8.3.3 Asia-Pacific Hematological Malignancy Drugs Market Share by Indication (2017-2028)
8.4 Asia-Pacific Hematological Malignancy Drugs Market Size by Region
8.4.1 Asia-Pacific Hematological Malignancy Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Hematological Malignancy Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hematological Malignancy Drugs Market Size (2017-2028)
9.2 Latin America Hematological Malignancy Drugs Market Size by Type
9.2.1 Latin America Hematological Malignancy Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Hematological Malignancy Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Hematological Malignancy Drugs Market Share by Type (2017-2028)
9.3 Latin America Hematological Malignancy Drugs Market Size by Indication
9.3.1 Latin America Hematological Malignancy Drugs Market Size by Indication (2017-2022)
9.3.2 Latin America Hematological Malignancy Drugs Market Size by Indication (2023-2028)
9.3.3 Latin America Hematological Malignancy Drugs Market Share by Indication (2017-2028)
9.4 Latin America Hematological Malignancy Drugs Market Size by Country
9.4.1 Latin America Hematological Malignancy Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Hematological Malignancy Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematological Malignancy Drugs Market Size (2017-2028)
10.2 Middle East & Africa Hematological Malignancy Drugs Market Size by Type
10.2.1 Middle East & Africa Hematological Malignancy Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Hematological Malignancy Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Hematological Malignancy Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Hematological Malignancy Drugs Market Size by Indication
10.3.1 Middle East & Africa Hematological Malignancy Drugs Market Size by Indication (2017-2022)
10.3.2 Middle East & Africa Hematological Malignancy Drugs Market Size by Indication (2023-2028)
10.3.3 Middle East & Africa Hematological Malignancy Drugs Market Share by Indication (2017-2028)
10.4 Middle East & Africa Hematological Malignancy Drugs Market Size by Country
10.4.1 Middle East & Africa Hematological Malignancy Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Hematological Malignancy Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Hematological Malignancy Drugs Introduction
11.1.4 Roche Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Celgene
11.2.1 Celgene Company Details
11.2.2 Celgene Business Overview
11.2.3 Celgene Hematological Malignancy Drugs Introduction
11.2.4 Celgene Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.2.5 Celgene Recent Developments
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Hematological Malignancy Drugs Introduction
11.3.4 Novartis Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.3.5 Novartis Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Hematological Malignancy Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Hematological Malignancy Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.5.5 Johnson & Johnson Recent Developments
11.6 Merck & Co.
11.6.1 Merck & Co. Company Details
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Hematological Malignancy Drugs Introduction
11.6.4 Merck & Co. Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.6.5 Merck & Co. Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Hematological Malignancy Drugs Introduction
11.7.4 AstraZeneca Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.7.5 AstraZeneca Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Hematological Malignancy Drugs Introduction
11.8.4 Pfizer Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.8.5 Pfizer Recent Developments
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Hematological Malignancy Drugs Introduction
11.9.4 Amgen Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.9.5 Amgen Recent Developments
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Hematological Malignancy Drugs Introduction
11.10.4 Eli Lilly Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.10.5 Eli Lilly Recent Developments
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Hematological Malignancy Drugs Introduction
11.11.4 AbbVie Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.11.5 AbbVie Recent Developments
11.12 Takeda
11.12.1 Takeda Company Details
11.12.2 Takeda Business Overview
11.12.3 Takeda Hematological Malignancy Drugs Introduction
11.12.4 Takeda Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.12.5 Takeda Recent Developments
11.13 Sanofi
11.13.1 Sanofi Company Details
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Hematological Malignancy Drugs Introduction
11.13.4 Sanofi Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.13.5 Sanofi Recent Developments
11.14 Bayer
11.14.1 Bayer Company Details
11.14.2 Bayer Business Overview
11.14.3 Bayer Hematological Malignancy Drugs Introduction
11.14.4 Bayer Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.14.5 Bayer Recent Developments
11.15 Biogen Idec
11.15.1 Biogen Idec Company Details
11.15.2 Biogen Idec Business Overview
11.15.3 Biogen Idec Hematological Malignancy Drugs Introduction
11.15.4 Biogen Idec Revenue in Hematological Malignancy Drugs Business (2017-2022)
11.15.5 Biogen Idec Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Hematological Malignancy Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Monoclonal Antibody
Table 3. Key Players of Immunomodulatory Drug
Table 4. Key Players of Tyrosine Kinase Inhibitor
Table 5. Key Players of Proteasome Inhibitors
Table 6. Key Players of Others
Table 7. Global Hematological Malignancy Drugs Market Size Growth Rate by Indication (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Hematological Malignancy Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Hematological Malignancy Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Hematological Malignancy Drugs Market Share by Region (2017-2022)
Table 11. Global Hematological Malignancy Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Hematological Malignancy Drugs Market Share by Region (2023-2028)
Table 13. Hematological Malignancy Drugs Market Trends
Table 14. Hematological Malignancy Drugs Market Drivers
Table 15. Hematological Malignancy Drugs Market Challenges
Table 16. Hematological Malignancy Drugs Market Restraints
Table 17. Global Hematological Malignancy Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Hematological Malignancy Drugs Revenue Share by Players (2017-2022)
Table 19. Global Top Hematological Malignancy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Malignancy Drugs as of 2021)
Table 20. Ranking of Global Top Hematological Malignancy Drugs Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Hematological Malignancy Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Hematological Malignancy Drugs Product Solution and Service
Table 24. Date of Enter into Hematological Malignancy Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Hematological Malignancy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Hematological Malignancy Drugs Revenue Market Share by Type (2017-2022)
Table 28. Global Hematological Malignancy Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Hematological Malignancy Drugs Revenue Market Share by Type (2023-2028)
Table 30. Global Hematological Malignancy Drugs Market Size by Indication (2017-2022) & (US$ Million)
Table 31. Global Hematological Malignancy Drugs Revenue Share by Indication (2017-2022)
Table 32. Global Hematological Malignancy Drugs Forecasted Market Size by Indication (2023-2028) & (US$ Million)
Table 33. Global Hematological Malignancy Drugs Revenue Share by Indication (2023-2028)
Table 34. North America Hematological Malignancy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Hematological Malignancy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Hematological Malignancy Drugs Market Size by Indication (2017-2022) & (US$ Million)
Table 37. North America Hematological Malignancy Drugs Market Size by Indication (2023-2028) & (US$ Million)
Table 38. North America Hematological Malignancy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Hematological Malignancy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Hematological Malignancy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Hematological Malignancy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Hematological Malignancy Drugs Market Size by Indication (2017-2022) & (US$ Million)
Table 43. Europe Hematological Malignancy Drugs Market Size by Indication (2023-2028) & (US$ Million)
Table 44. Europe Hematological Malignancy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Hematological Malignancy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Hematological Malignancy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Hematological Malignancy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Hematological Malignancy Drugs Market Size by Indication (2017-2022) & (US$ Million)
Table 49. Asia Pacific Hematological Malignancy Drugs Market Size by Indication (2023-2028) & (US$ Million)
Table 50. Asia Pacific Hematological Malignancy Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Hematological Malignancy Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Hematological Malignancy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Hematological Malignancy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Hematological Malignancy Drugs Market Size by Indication (2017-2022) & (US$ Million)
Table 55. Latin America Hematological Malignancy Drugs Market Size by Indication (2023-2028) & (US$ Million)
Table 56. Latin America Hematological Malignancy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Hematological Malignancy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Hematological Malignancy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Hematological Malignancy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Hematological Malignancy Drugs Market Size by Indication (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Hematological Malignancy Drugs Market Size by Indication (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Hematological Malignancy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Hematological Malignancy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Hematological Malignancy Drugs Product
Table 67. Roche Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 68. Roche Recent Developments
Table 69. Celgene Company Details
Table 70. Celgene Business Overview
Table 71. Celgene Hematological Malignancy Drugs Product
Table 72. Celgene Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 73. Celgene Recent Developments
Table 74. Novartis Company Details
Table 75. Novartis Business Overview
Table 76. Novartis Hematological Malignancy Drugs Product
Table 77. Novartis Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 78. Novartis Recent Developments
Table 79. Bristol-Myers Squibb Company Details
Table 80. Bristol-Myers Squibb Business Overview
Table 81. Bristol-Myers Squibb Hematological Malignancy Drugs Product
Table 82. Bristol-Myers Squibb Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 83. Bristol-Myers Squibb Recent Developments
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Hematological Malignancy Drugs Product
Table 87. Johnson & Johnson Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 88. Johnson & Johnson Recent Developments
Table 89. Merck & Co. Company Details
Table 90. Merck & Co. Business Overview
Table 91. Merck & Co. Hematological Malignancy Drugs Product
Table 92. Merck & Co. Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 93. Merck & Co. Recent Developments
Table 94. AstraZeneca Company Details
Table 95. AstraZeneca Business Overview
Table 96. AstraZeneca Hematological Malignancy Drugs Product
Table 97. AstraZeneca Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 98. AstraZeneca Recent Developments
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Hematological Malignancy Drugs Product
Table 102. Pfizer Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 103. Pfizer Recent Developments
Table 104. Amgen Company Details
Table 105. Amgen Business Overview
Table 106. Amgen Hematological Malignancy Drugs Product
Table 107. Amgen Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 108. Amgen Recent Developments
Table 109. Eli Lilly Company Details
Table 110. Eli Lilly Business Overview
Table 111. Eli Lilly Hematological Malignancy Drugs Product
Table 112. Eli Lilly Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 113. Eli Lilly Recent Developments
Table 114. AbbVie Company Details
Table 115. AbbVie Business Overview
Table 116. AbbVie Hematological Malignancy Drugs Product
Table 117. AbbVie Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 118. AbbVie Recent Developments
Table 119. Takeda Company Details
Table 120. Takeda Business Overview
Table 121. Takeda Hematological Malignancy Drugs Product
Table 122. Takeda Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 123. Takeda Recent Developments
Table 124. Sanofi Company Details
Table 125. Sanofi Business Overview
Table 126. Sanofi Hematological Malignancy Drugs Product
Table 127. Sanofi Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 128. Sanofi Recent Developments
Table 129. Bayer Company Details
Table 130. Bayer Business Overview
Table 131. Bayer Hematological Malignancy Drugs Product
Table 132. Bayer Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 133. Bayer Recent Developments
Table 134. Biogen Idec Company Details
Table 135. Biogen Idec Business Overview
Table 136. Biogen Idec Hematological Malignancy Drugs Product
Table 137. Biogen Idec Revenue in Hematological Malignancy Drugs Business (2017-2022) & (US$ Million)
Table 138. Biogen Idec Recent Developments
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hematological Malignancy Drugs Market Share by Type: 2021 VS 2028
Figure 2. Monoclonal Antibody Features
Figure 3. Immunomodulatory Drug Features
Figure 4. Tyrosine Kinase Inhibitor Features
Figure 5. Proteasome Inhibitors Features
Figure 6. Others Features
Figure 7. Global Hematological Malignancy Drugs Market Share by Indication: 2021 VS 2028
Figure 8. ALL Case Studies
Figure 9. CLL Case Studies
Figure 10. AML Case Studies
Figure 11. NHL Case Studies
Figure 12. DLBCL Case Studies
Figure 13. MM Case Studies
Figure 14. Others Case Studies
Figure 15. Hematological Malignancy Drugs Report Years Considered
Figure 16. Global Hematological Malignancy Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 17. Global Hematological Malignancy Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Hematological Malignancy Drugs Market Share by Region: 2021 VS 2028
Figure 19. Global Hematological Malignancy Drugs Market Share by Players in 2021
Figure 20. Global Top Hematological Malignancy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hematological Malignancy Drugs as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Hematological Malignancy Drugs Revenue in 2021
Figure 22. North America Hematological Malignancy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 23. North America Hematological Malignancy Drugs Market Size Market Share by Type (2017-2028)
Figure 24. North America Hematological Malignancy Drugs Market Size Market Share by Indication (2017-2028)
Figure 25. North America Hematological Malignancy Drugs Market Size Share by Country (2017-2028)
Figure 26. United States Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Canada Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Europe Hematological Malignancy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 29. Europe Hematological Malignancy Drugs Market Size Market Share by Type (2017-2028)
Figure 30. Europe Hematological Malignancy Drugs Market Size Market Share by Indication (2017-2028)
Figure 31. Europe Hematological Malignancy Drugs Market Size Share by Country (2017-2028)
Figure 32. Germany Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. France Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. U.K. Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Italy Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Russia Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Nordic Countries Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Asia-Pacific Hematological Malignancy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 39. Asia Pacific Hematological Malignancy Drugs Market Size Market Share by Type (2017-2028)
Figure 40. Asia Pacific Hematological Malignancy Drugs Market Size Market Share by Indication (2017-2028)
Figure 41. Asia Pacific Hematological Malignancy Drugs Market Size Share by Region (2017-2028)
Figure 42. China Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Japan Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. South Korea Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Southeast Asia Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. India Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Australia Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 48. Latin America Hematological Malignancy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Latin America Hematological Malignancy Drugs Market Size Market Share by Type (2017-2028)
Figure 50. Latin America Hematological Malignancy Drugs Market Size Market Share by Indication (2017-2028)
Figure 51. Latin America Hematological Malignancy Drugs Market Size Share by Country (2017-2028)
Figure 52. Mexico Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Brazil Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Middle East & Africa Hematological Malignancy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 55. Middle East and Africa Hematological Malignancy Drugs Market Size Market Share by Type (2017-2028)
Figure 56. Middle East and Africa Hematological Malignancy Drugs Market Size Market Share by Indication (2017-2028)
Figure 57. Middle East and Africa Hematological Malignancy Drugs Market Size Share by Country (2017-2028)
Figure 58. Turkey Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 59. Saudi Arabia Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 60. UAE Hematological Malignancy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 61. Roche Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 62. Celgene Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 63. Novartis Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 65. Johnson & Johnson Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 66. Merck & Co. Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 67. AstraZeneca Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 68. Pfizer Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 69. Amgen Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 70. Eli Lilly Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 71. AbbVie Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 72. Takeda Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 73. Sanofi Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 74. Bayer Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 75. Biogen Idec Revenue Growth Rate in Hematological Malignancy Drugs Business (2017-2022)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

以下、関連資料のご紹介

C型肝炎ウイルス治療薬のグローバル市場インサイト・予測（～2028年）

Global Hepatitis C Virus Drugs Market Insights, Forecast to 2028
MRC2Q12-19108 2022年12月 94Pages
コロナ禍により、C型肝炎ウイルス治療薬の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にC型肝炎ウイルス治療薬のグローバル市場のxxx...

肉腫治療薬剤のグローバル市場インサイト・予測（～2028年）

Global Sarcoma Drugs Market Insights, Forecast to 2028
MRC2Q12-16843 2022年12月 111Pages
コロナ禍により、肉腫治療薬剤の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に肉腫治療薬剤のグローバル市場のxxx％を占める「ビンクリ...

新型コロナウイルス感染症小分子薬のグローバル市場インサイト・予測（～2028年）

Global Covid-19 Small Molecule Drugs Market Insights, Forecast to 2028
QY2207C3862 2022年7月11日 88Pages
新型コロナウイルス感染症のパンデミックにより、世界の新型コロナウイルス感染症小分子薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に新型...

小児用希少疾病用医薬品のグローバル市場インサイト・予測（～2028年）

Global Pediatric Orphan Drugs Market Insights, Forecast to 2028
MRC2Q12-16821 2022年12月 114Pages
コロナ禍により、小児用希少疾病用医薬品の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に小児用希少疾病用医薬品のグローバル市場のxxx...

血友病治療薬のグローバル市場（2023年-2031年）：遺伝子組換え凝固因子濃縮製剤、血漿由来凝固因子濃縮製剤、その他

Hemophilia Treatment Drugs Market (Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
MRC2401A117 2023年11月 188Pages
血友病治療薬市場-レポート範囲
TMRの調査レポート「世界の血友病治療薬市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から203...